Darryl Sleep on Collaboration and Partnership Across the Entire HHT Community: Patients Can’t Wait!
Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Azmi Nabulsi on LinkedIn:
”I am honored to be part of a dedicated team committed to developing focused, targeted therapeutics to address significant unmet medical need patients living with HHT.
The collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers is truly inspiring.
All stakeholders work together with urgency and a deep commitment to improve the lives patients living with HHT.
Patients can’t wait!”
Quoting Azmi Nabulsi‘s post:
”It’s a proud moment for our team to see the engasertib data published in The New England Journal of Medicine.
This recognition validates the strength of the science, the rigor behind the work, and the potential impact for the HHT community.
Thank you to our team, our investigators, and the patients who made this possible.
We now move into the next phase with clarity and confidence as we advance toward our Phase 3 study in 2026.”
Stay updated with Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines